LYPHF (Luye Pharma Group) Beta: 0.2345 (As of Jun. 24, 2026)


LYPHF Luye Pharma Group Ltd LYPHF
58 GF Score
Price $0.20
GF Value $0.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group Beta?

Luye Pharma Group LYPHF 58 Beta is 0.2345 as of Jun. 24, 2026. GuruFocus rates LYPHF with a GF Score™ of 58/100 and a GF Value™ of $0.33 (Possible Value Trap). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Luye Pharma Group's Beta is 0.2345.


Luye Pharma Group  (OTCPK:LYPHF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Luye Pharma Group Beta Related Terms


Luye Pharma Group Beta Historical Data

* Premium members only.

The historical data trend for Luye Pharma Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Luye Pharma Group Beta Chart

Luye Pharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.05 0.52

Luye Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.02 0.05 0.37 0.52

LYPHF vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Beta distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Beta falls into.


LYPHF
58GF Score
Luye Pharma Group Ltd LYPHF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Luye Pharma Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2345 mean?
Luye Pharma Group (LYPHF) has a Beta of 0.2345 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Luye Pharma Group and its competitors.
Is Luye Pharma Group's Beta too high?
Luye Pharma Group's current Beta is 0.2345. Overall, Luye Pharma Group has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Beta compare to ZTS?
Luye Pharma Group's Beta of 0.2345 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Luye Pharma Group and its competitors. Luye Pharma Group's current Beta is 0.2345. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (LYPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.33, compared to a current price of $0.20 — trading 38.2% below its estimated fair value. The current Beta is 0.2345. Luye Pharma Group's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Luye Pharma Group (LYPHF), the current Beta is 0.2345 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Luye Pharma Group (LYPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of $0.20 is trading 38.2% below its estimated GF Value™ of $0.33. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for LYPHF:

  • Beta: 0.2345
  • GF Value™: $0.33 vs. price of $0.20 (38.2% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the LYPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Luye Pharma Group Business Description

Other Exchanges 02186:Hong KongLUP:Germany
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
58GF Score

Get the complete analysis for LYPHF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.33
GF Value